ES2796839T3 - Uso de péptidos GLP-1 de acción prolongada - Google Patents
Uso de péptidos GLP-1 de acción prolongada Download PDFInfo
- Publication number
- ES2796839T3 ES2796839T3 ES13737808T ES13737808T ES2796839T3 ES 2796839 T3 ES2796839 T3 ES 2796839T3 ES 13737808 T ES13737808 T ES 13737808T ES 13737808 T ES13737808 T ES 13737808T ES 2796839 T3 ES2796839 T3 ES 2796839T3
- Authority
- ES
- Spain
- Prior art keywords
- glp
- agonist
- composition
- use according
- semaglutide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 title 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims abstract description 99
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 108010060325 semaglutide Proteins 0.000 claims abstract description 49
- 229950011186 semaglutide Drugs 0.000 claims abstract description 49
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000002265 prevention Effects 0.000 claims abstract description 26
- 208000008589 Obesity Diseases 0.000 claims abstract description 16
- 235000020824 obesity Nutrition 0.000 claims abstract description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000013011 aqueous formulation Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 5
- 230000037396 body weight Effects 0.000 claims description 32
- 239000000872 buffer Substances 0.000 claims description 18
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 description 44
- 238000000034 method Methods 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 238000003556 assay Methods 0.000 description 25
- 108010019598 Liraglutide Proteins 0.000 description 23
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 23
- 229960002701 liraglutide Drugs 0.000 description 23
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 23
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 22
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 22
- 229940095074 cyclic amp Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000000902 placebo Substances 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000037406 food intake Effects 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 235000012631 food intake Nutrition 0.000 description 15
- 238000003016 alphascreen Methods 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000011324 bead Substances 0.000 description 13
- 230000036515 potency Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 11
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 10
- 208000002705 Glucose Intolerance Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 201000009104 prediabetes syndrome Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 244000309715 mini pig Species 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000036186 satiety Effects 0.000 description 8
- 235000019627 satiety Nutrition 0.000 description 8
- 108010011459 Exenatide Proteins 0.000 description 7
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 229960001519 exenatide Drugs 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 4
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005465 channeling Effects 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002473 insulinotropic effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- -1 pH 7.4 Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 description 1
- LWMBPKJYEQGDLN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;piperazine;hydrate Chemical compound O.C1CNCCN1.C1CNCCN1.C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O LWMBPKJYEQGDLN-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 101001116436 Mus musculus Xaa-Pro dipeptidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 108090000083 Serine Endopeptidases Proteins 0.000 description 1
- 102000003667 Serine Endopeptidases Human genes 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229940014641 bydureon Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940098946 vaginal ointment Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| EP12186781 | 2012-10-01 | ||
| PCT/EP2013/063004 WO2014005858A1 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2796839T3 true ES2796839T3 (es) | 2020-11-30 |
Family
ID=65858459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13737808T Active ES2796839T3 (es) | 2012-07-01 | 2013-06-21 | Uso de péptidos GLP-1 de acción prolongada |
| ES20157813T Active ES3041720T3 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20157813T Active ES3041720T3 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (enExample) |
| EP (3) | EP3689365B1 (enExample) |
| JP (1) | JP6059802B2 (enExample) |
| AU (3) | AU2013286177B2 (enExample) |
| BR (1) | BR112014032938A2 (enExample) |
| CA (1) | CA2877056A1 (enExample) |
| DK (1) | DK2866825T3 (enExample) |
| ES (2) | ES2796839T3 (enExample) |
| HR (2) | HRP20200889T1 (enExample) |
| HU (1) | HUE049152T2 (enExample) |
| MX (3) | MX376058B (enExample) |
| PL (2) | PL3689365T3 (enExample) |
| PT (1) | PT2866825T (enExample) |
| RS (2) | RS67258B1 (enExample) |
| RU (2) | RU2657573C2 (enExample) |
| SI (1) | SI2866825T1 (enExample) |
| WO (1) | WO2014005858A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3326620T3 (pl) | 2010-12-16 | 2020-08-24 | Novo Nordisk A/S | Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| HUE062740T2 (hu) | 2012-03-22 | 2023-12-28 | Novo Nordisk As | GLP-1 peptidek készítményei és elõállításuk |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| DK2866825T3 (da) | 2012-07-01 | 2020-06-08 | Novo Nordisk As | Anvendelse af langstidsvirkende glp-1-peptider |
| PT2991671T (pt) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| US10543843B2 (en) * | 2014-10-16 | 2020-01-28 | Yanmar Co., Ltd. | Work vehicle |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| JP6633777B2 (ja) | 2017-08-24 | 2020-01-22 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物及びその使用 |
| MA50358A (fr) * | 2017-10-12 | 2020-08-19 | Novo Nordisk As | Sémaglutide en thérapie médicale |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| SG11202006595RA (en) | 2018-02-02 | 2020-08-28 | Novo Nordisk As | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| WO2020028907A1 (en) * | 2018-08-03 | 2020-02-06 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| EP3930753A4 (en) * | 2019-02-26 | 2023-03-29 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR GLP1 RECEPTOR |
| KR20220110731A (ko) * | 2019-11-06 | 2022-08-09 | 노보 노르디스크 에이/에스 | 치매에서의 glp-1 수용체 작용제 |
| KR20220119731A (ko) * | 2019-12-30 | 2022-08-30 | 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 | 장기 지속형 glp-1 화합물 |
| AU2021208601B2 (en) * | 2020-02-18 | 2025-06-05 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| US20240285729A1 (en) * | 2021-06-24 | 2024-08-29 | Gila Therapeutics, Inc. | Methods and kits for inducing satiety and treating metabolic disorders |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US20230150998A1 (en) | 2021-09-27 | 2023-05-18 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| AU2022386166A1 (en) | 2021-11-10 | 2024-06-20 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| CN115850438B (zh) * | 2021-12-28 | 2023-05-12 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| WO2025024455A1 (en) | 2023-07-24 | 2025-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１誘導体 |
| DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| CN102784386A (zh) | 2003-11-20 | 2012-11-21 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| JP5175103B2 (ja) | 2004-11-12 | 2013-04-03 | ノヴォ ノルディスク アー／エス | 安定なペプチド製剤 |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2008013216A (es) | 2006-04-14 | 2008-10-27 | Mannkind Corp | Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1). |
| EP2121897A4 (en) | 2007-03-20 | 2010-03-31 | Nippon Kayaku Kk | METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| LT2373681T (lt) | 2008-12-10 | 2017-04-10 | Glaxosmithkline Llc | Albiglutido farmacinės kompozicijos |
| NZ594044A (en) * | 2009-02-13 | 2014-08-29 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JP2013514322A (ja) * | 2009-12-16 | 2013-04-25 | ノヴォ ノルディスク アー／エス | 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物 |
| KR101819609B1 (ko) * | 2010-05-05 | 2018-01-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| PL3326620T3 (pl) | 2010-12-16 | 2020-08-24 | Novo Nordisk A/S | Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| JP2014520159A (ja) * | 2011-06-24 | 2014-08-21 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法 |
| DK2866825T3 (da) | 2012-07-01 | 2020-06-08 | Novo Nordisk As | Anvendelse af langstidsvirkende glp-1-peptider |
-
2013
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2796839T3 (es) | Uso de péptidos GLP-1 de acción prolongada | |
| TWI596110B (zh) | 新穎升糖素類似物 | |
| CN106715466B (zh) | 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物 | |
| CN1551780A (zh) | 用于预防或治疗体重过重的胃肠激素 | |
| US20160136246A1 (en) | Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes | |
| ES2767705T3 (es) | Nuevos análogos de glucagón |